



Acta Medica Europa

Calcium Oxalate Kidney Stones

Jin Ho Park ¹

¹ Specialist of Urology, Seoul, Republic of Korea

Article Info

Received: 19 September 2019

Accepted: 23 September 2019

Published: 25 September 2019

Keywords:

Calcium oxalate, kidney stones, nephrolithiasis, stone formation.

Corresponding author:

Jin Ho Park

Specialist of Urology, Seoul,
Republic of Korea

dr.parkjinho84@gmail.com

ABSTRACT

Calcium oxalate (CaOx) kidney stones torment millions worldwide, posing significant clinical and economic burdens. This mini-review delves into the intricate world of CaOx stone formation, dissecting the interplay of risk factors, exploring current management strategies, and illuminating emerging frontiers in prevention and treatment.

Introduction

CaOx stones account for around 75% of all kidney stones, posing a major public health challenge. Understanding the multifactorial cascade leading to their formation is crucial for developing effective preventative and therapeutic approaches (1-5).

Mechanisms of CaOx Stone Formation

Supersaturation: High urinary concentrations of calcium and oxalate, influenced by dietary intake, metabolic imbalances, and dehydration, contribute to crystal nucleation. **Crystal growth:** Aggregates of microscopic CaOx crystals grow into larger structures, facilitated by low urine pH and reduced citrate levels. **Inhibitors and promoters:** Citrate, magnesium, and glycosaminoglycans naturally inhibit crystal growth, while acidic pH, low urine volume, and certain proteins promote it (6-9).

Risk Factors and Diagnosis

Genetic predisposition, dietary habits (e.g., high protein, low-calcium, low-fluid intake), certain medical conditions (e.g., obesity, hyperthyroidism), and medications increase CaOx stone susceptibility. Early diagnosis, employing imaging

techniques like ultrasound or CT scans, allows for stone characterization and guides management (10-14).

Current Management Strategies

Fluid optimization: Increased water intake dilutes urine and reduces stone risk.

Dietary modifications: Tailored diet plans limiting oxalate and promoting citrate intake aim to prevent crystal formation.

Medical therapy: Medications like potassium citrate or thiazides modify urine pH and decrease crystal growth in specific cases.

Extracorporeal Shock Wave Lithotripsy (ESWL): Non-invasive fragmentation of small stones using focused shock waves. **Ureterscopy with Laser Lithotripsy:** Removal of obstructing stones through the ureter using a scope and laser to fragment them. **Percutaneous Nephrolithotomy (PCNL):** Surgical approach for large or complex stones, accessing the kidney directly through a small incision (7-11).

Emerging Horizons:

Nanomedicine: Nanoparticle-based therapies for non-invasive stone detection and targeted dissolution hold promise for future management (1-3).

Genetic testing: Identifying inherited mutations linked to CaOx stone formation may pave the way for personalized prevention and early intervention.

Microbiome modulation: Exploring the gut microbiome's role in stone formation and manipulating it through probiotics or prebiotics could offer novel preventative strategies.

Personalized medicine: Tailoring preventative and therapeutic approaches based on individual risk factors, genetic makeup, and metabolic profiles (11-14).

Conclusion

CaOx kidney stones remain a significant challenge, demanding a multi-pronged approach. Ongoing research into mechanisms, improved diagnostic tools, and innovative therapeutic avenues are key to optimizing clinical outcomes and alleviating the burden of this prevalent condition. Embracing personalized medicine and harnessing emerging technologies promise a brighter future for preventing and managing CaOx stones, offering hope to millions living with this painful and debilitating condition.

REFERENCES

1. Yang Y, Hong S, Lu Y, Wang Q, Wang S, Xun Y. CAV1 alleviated CaOx stones formation via suppressing autophagy-dependent ferroptosis. *PeerJ*. 2022;10:e14033. Published 2022 Sep 15. doi:10.7717/peerj.14033
2. Li S, Macaringue EGI, Zhou D, Shi P, Tang W, Gong J. Discovering inhibitor molecules for pathological crystallization of CaOx kidney stones from natural extracts of medical herbs. *J Ethnopharmacol*. 2022;284:114733. doi:10.1016/j.jep.2021.114733
3. An LY, He ZC, Chang ZL, Huang YP, Zhang SK, Wu WQ. Bacteria-mediated TRPV5 activity promote kidney CaOx stones: a story too good to be true?. *Am J Physiol Renal Physiol*. 2020;318(2):F506. doi:10.1152/ajprenal.00534.2019
4. Domingos F, Serra A. Metabolic syndrome: a multifaceted risk factor for kidney stones. *Scand J Urol*. 2014;48(5):414-419. doi:10.3109/21681805.2014.903513
5. Cheungpasitporn W, Thongprayoon C, Mao MA, et al. Incidence of kidney stones in kidney transplant recipients: A systematic review and meta-analysis. *World J Transplant*. 2016;6(4):790-797. doi:10.5500/wjt.v6.i4.790
6. Baumann JM, Affolter B. From crystalluria to kidney stones, some physicochemical aspects of calcium nephrolithiasis. *World J Nephrol*. 2014;3(4):256-267. doi:10.5527/wjn.v3.i4.256
7. Schwaderer AL, Wolfe AJ. The association between bacteria and urinary stones. *Ann Transl Med*. 2017;5(2):32. doi:10.21037/atm.2016.11.73
8. Hess B. Metabolic syndrome, obesity and kidney stones. *Arab J Urol*. 2012;10(3):258-264. doi:10.1016/j.aju.2012.04.005
9. Robertson WG. Do "inhibitors of crystallisation" play any role in the prevention of kidney stones? A critique. *Urolithiasis*. 2017;45(1):43-56. doi:10.1007/s00240-016-0953-y
10. Liang L, Li L, Tian J, et al. Androgen receptor enhances kidney stone-CaOx crystal formation via modulation of oxalate biosynthesis & oxidative stress. *Mol Endocrinol*. 2014;28(8):1291-1303. doi:10.1210/me.2014-1047
11. Dominguez-Gutierrez PR, Kwenda EP, Khan SR, Canales BK. Immunotherapy for stone disease. *Curr Opin Urol*. 2020;30(2):183-189. doi:10.1097/MOU.0000000000000729
12. Ye QL, Wang DM, Wang X, et al. Sirt1 inhibits kidney stones formation by attenuating calcium oxalate-induced cell injury. *Chem Biol Interact*. 2021;347:109605. doi:10.1016/j.cbi.2021.109605
13. Du Y, Roger VB, Mena J, Kang M, Stoller ML, Ho SP. Structural and chemical heterogeneities of primary hyperoxaluria kidney stones from pediatric patients. *J Pediatr Urol*. 2021;17(2):214.e1-214.e11. doi:10.1016/j.jpuro.2020.11.023
14. Yang Y, Hong S, Xu J, Li C, Wang S, Xun Y. Enterobacter cloacae: a villain in CaOx stone disease?. *Urolithiasis*. 2022;50(2):177-188. doi:10.1007/s00240-022-01311-8 Tsai SC, Lu CC, Bau DT, et al. Approaches towards fighting the COVID-19 pandemic (Review). *Int J Mol Med*. 2021;47(1):3-22. doi:10.3892/ijmm.2020.4794